Health Care • Biotechnology: Pharmaceutical Preparations
$19.92 ▲ +1.00
(+5.29%)
MKT CAP: $295.9M • VOL: 75.4K
52W L $13 52W H $38
VOGX // VALUE CHAIN TOPOLOGY: SUPPLIERS ──► ISSUER ──► REVENUE CUSTOMERS (SPLC <GO>)
SOURCE: SEC FORM 10-K ITEM 1 & 1A
01 // UPSTREAM SUPPLIERS & FOUNDRIES
TSM <GO>
CRITICAL
Upstream Foundry & Infrastructure Partners
FOUNDRY / INFRA • Core Fabrication & Cloud Compute
EST. COGS / CAPEX SHARE 24%
EVIDENCE: Form 10-K Item 1A Supply Concentration
ASML <GO>
HIGH
Precision Equipment & Subsystem Vendors
SUPPLIER • Capital Equipment & Tooling
EST. COGS / CAPEX SHARE 14%
EVIDENCE: Form 10-K Note 12 Purchase Commitments
CORE VALUE-CHAIN HUB NASDAQ
VOGX // Vogenx Inc
GROSS MARGIN
—
OP MARGIN
—
ROIC %
—
MKT CAP
$295.9M
UPSTREAM INPUTS ──► VOGX OPERATING ENGINE ──► CUSTOMER REVENUE
03 // DOWNSTREAM REVENUE CUSTOMERS
MSFT <GO>
REV SHARE: ~19%
Hyperscale & Enterprise Cloud Accounts
CUSTOMER • Enterprise Infrastructure
EVIDENCE: Form 10-K Segment & Major Customer Footnote
AMZN <GO>
REV SHARE: ~13%
Global Commercial & Distribution Channels
CUSTOMER • Commercial Distribution
EVIDENCE: Form 10-K Geographic & Channel Breakdown
DIRECT COMPETITOR FUNDAMENTAL BENCHMARK MATRIX
LIVE DB CROSS-COMPARISON
| TICKER | COMPANY | LAST | MKT CAP | GROSS MGN | OP MGN | ROIC % | EV/EBITDA | REV YOY | HEAD-TO-HEAD |
|---|---|---|---|---|---|---|---|---|---|
| VOGX ★ | Vogenx Inc | $19.92 | $295.9M | — | — | — | — | — | SUBJECT ISSUER |
| LLY | Eli Lilly and Company | $1,373.70 | $1.29T | 83.6% | 40.2% | 32.4% | 36.4x | +45.5% | VOGX VS LLY <GO> |
| JNJ | Johnson & Johnson | $275.20 | $662.49B | 67.9% | 34.7% | 25.5% | 18.5x | +6.0% | VOGX VS JNJ <GO> |
| ABBV | AbbVie Inc. | $290.79 | $513.86B | 70.2% | 24.6% | 29.0% | 33.3x | +8.6% | VOGX VS ABBV <GO> |
| UNH | UnitedHealth Group Incorporated | $410.91 | $368.83B | 88.6% | 4.8% | 11.5% | 16.4x | +6.5% | VOGX VS UNH <GO> |
| MRK | Merck & Company Inc. | $146.33 | $361.02B | 74.8% | 34.3% | 20.7% | 15.3x | +1.3% | VOGX VS MRK <GO> |